Drug Profile
Orelabrutinib - InnoCare Pharma
Alternative Names: BIIB-135; ICP 022; INNOBRUKA; YINUOKAILatest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator InnoCare Pharma
- Class Amides; Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Phenyl ethers; Piperidines; Pyridines; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
- Preregistration Waldenstrom's macroglobulinaemia
- Phase III Diffuse large B cell lymphoma; Idiopathic thrombocytopenic purpura
- Phase II Lymphoma; Multiple sclerosis; Neuromyelitis optica; Non-Hodgkin's lymphoma; Systemic lupus erythematosus
- Phase I/II B-cell lymphoma; Follicular lymphoma
- Phase I Liver disorders
- Discontinued Rheumatoid arthritis
Most Recent Events
- 12 Apr 2024 InnoCare Pharma plans a phase III trial for Mantle cell lymphoma (Combination therapy, Treatment-naïve, First line therapy, Late stage disease) (PO), in May 2024 (NCT06363994)
- 28 Mar 2024 InnoCare Pharma announces intention to submit New Drug Application (NDA) for Chronic lymphocytic leukaemia (First-line therapy) in the third quarter of 2024
- 28 Mar 2024 InnoCare Pharma plans to submit NDA in Mantle-cell lymphoma (Second-line therapy or greater) in USA in the third quarter of 2024